-+ 0.00%
-+ 0.00%
-+ 0.00%

Bristol-Myers Squibb: In phase 3 breast cancer studies, isabemumab reduced the risk of disease progression or death by 59%.

Zhitongcaijing·10/23/2026 11:33:24
Listen to the news
Bristol-Myers Squibb: In phase 3 breast cancer studies, isabemumab reduced the risk of disease progression or death by 59%.